Success Metrics

Mar 30, 2026

Daniel Meursing

12 mins Read

How a Fitness Brand Built a Peptide Revenue Channel

Core Insights

Introduction

A fitness and performance brand with a loyal online community had been selling supplements for three years. The audience was engaged, evidence-driven, and had the disposable income to act on new programs. Peptide interest had been building organically in the community: BPC-157 questions, recovery protocol threads, requests for structured programs, without any direct brand promotion.

Several posts about peptide-supported recovery generated more engagement than any product launch in the previous 12 months. Comments were specific. The audience was not casually curious. They were asking about dosing windows, sourcing, and clinical oversight. That signal was significant. It meant demand already existed inside an audience the brand had spent three years building.

The operator wanted to convert that organic demand into a compliant revenue channel. The constraint was doing it without pivoting away from supplements, without adding clinical headcount, and without a public misstep that could damage years of audience trust.

The Challenge

The brand had no experience with prescription products. Peptides prescribed through a telehealth workflow operate in a completely different regulatory category from supplements. Provider credentialing, compounding pharmacy relationships, HIPAA infrastructure, and async clinical review are all required before the first patient can be served compliantly.

Getting this wrong publicly carried real risk. The brand had built its reputation on evidence-based content and product integrity. Recommending a clinical program that failed on compliance or fulfillment would have damaged three years of audience trust in a category where trust is the product.

The second constraint was margin. Supplement margins are high. The brand's existing business model was built around those margins, and any new program needed to meet or exceed that profile to justify the additional operational complexity. That meant pricing and fee structure had to be confirmed before any program design began, not after the first cohort enrolled.

The operator needed a path that solved all three constraints simultaneously: compliant clinical infrastructure, margin confirmation before launch, and a brand-safe rollout that did not expose the audience to an untested program.

Step 1 — Program Category Selection

The operator worked with FuseHealth to identify which peptide categories were available within the configured provider network and compounding pharmacy standing. The selection criteria were specific: compounds with the highest clinical relevance to a performance and recovery audience, validated against existing community engagement data.

This was not a catalog browse. The engagement data from the community, the specific compounds being discussed, the recovery use cases generating the most questions, drove the selection. Programs were matched to documented audience demand, not assumed interest.

Confirming program category before intake design meant the clinical workflow, the intake form logic, and the pharmacy routing were all built around a validated product offering. It also meant provider review costs were known before pricing was set.

Step 2 — Intake and Qualification

The intake form was built to qualify patients for the specific peptide protocols in sufficient clinical depth to enable efficient async provider review, minimizing back-and-forth that drives up provider costs and erodes program margin.

An intake form that collects too little information forces providers to request additional documentation before approving a case. Every additional exchange increases provider cost per case and erodes margin at scale. An intake form that collects irrelevant information increases patient abandonment before completion, reducing conversion from traffic to enrolled patient.

The Fuse Health intake design balanced both constraints. Patients moved through a structured qualification flow that gathered the clinical information providers needed to review cases efficiently, without adding friction that reduced completion rates. The result was a provider review queue that moved at volume without manual coordination from the operator.

Step 3— Community-First Launch

The program launched to the existing community before any paid acquisition spend was committed. This was a deliberate sequencing decision, not a shortcut. The first cohort came entirely from warm organic channels: email, owned social, and community posts, to validate pricing, intake conversion, and program structure before paid budget was introduced.

Launching to a warm audience first serves two functions. It validates the economics with the lowest possible customer acquisition cost, and it generates real retention data before the program scales. If pricing needs adjustment or fulfillment has friction, a warm-audience cohort surfaces it at low cost. A cold paid acquisition campaign surfaces the same problems at significantly higher cost, after the operator has already committed budget.

The community had already demonstrated organic demand for this category. That meant the first cohort was not a test of whether the audience wanted the program. It was a test of whether the program delivered on the expectation the community had already built around it.

Validated Program Pricing — Margin was confirmed against platform fees before launch. Pricing held through the first cohort without adjustment.

Community-First Revenue — The first cohort came entirely from existing community members. Customer acquisition cost on the first cohort was near zero.

90-Day Protocol Structure — Protocol-based programs create commitment at enrollment, driving meaningfully higher retention than open-ended subscriptions.

Blended LTV Increase — Peptide subscribers maintained supplement purchase behavior, increasing total annual spend per customer.

Zero Clinical Overhead: No providers were hired, credentialed, or managed by the operator. All prescription review and fulfillment ran through FuseHealth infrastructure from day one.

Build Your Telehealth Platform Faster

Launching digital healthcare services requires complex infrastructure. Fuse provides the tools needed to connect patients, providers, and pharmacies in one platform.

Step 4 — Subscription and Margin Design

Programs were structured as 90-day protocols with monthly refill billing, priced above the supplement average order value. The pricing model was built around three inputs: the Fuse Health platform fee structure, the per-case provider review cost, and the pharmacy fulfillment cost per unit. Margin was calculated and confirmed against all three before the program was offered to patients.

The 90-day protocol structure was a deliberate retention design choice, not a default. Open-ended subscriptions require patients to make an active reorder decision every month. Protocol-based programs frame enrollment as a defined treatment course. Patients commit to a specific outcome over a specific period. That framing reduces voluntary churn from patients who deprioritize the subscription during a busy month, because they are not making a monthly reorder decision. They enrolled in a program.

No pricing adjustments were needed after the first cohort enrolled. The unit economics held exactly as modeled. This outcome is significantly more likely when margin is confirmed before launch rather than validated through live cohort data after patients have already enrolled at a price point that may not hold at scale.

What Launched

The peptide program launched within six weeks of the initial FuseHealth onboarding session. The first cohort was entirely from existing community members with no paid acquisition spend. Monthly recurring revenue from the program exceeded the best supplement product launch in the brand's history within 90 days of going live.

The brand hired no clinical staff at any point during the process. Prescription review, pharmacy fulfillment, refill management, and patient notifications all ran through FuseHealth infrastructure. The operator's team focused entirely on community communication and acquisition strategy, the functions they were already built to execute well.

The program did not replace the supplement business. It ran alongside it. Customers who were active in both channels, purchasing supplements and enrolled in the peptide program, showed meaningfully higher total annual spend than customers in either channel alone. Adding a clinical revenue layer did not cannibalize the existing business. It compounded it.

Core Insights

The peptide program launched six weeks after onboarding began. Monthly recurring revenue exceeded the best supplement product launch in the brand's history within 90 days. The brand did not hire any clinical staff. Prescription review, pharmacy fulfillment, and refill management ran through FuseHealth. The operator managed the community and acquisition strategy.

Supplement brands with engaged audiences are sitting on demand they have not monetized. The community questions, the recovery threads, the organic interest in clinical programs: that signal is real, and it exists across a large number of fitness and wellness audiences built around evidence-based content. The gap between that demand and a launched prescription program is not clinical expertise. It is infrastructure.

Provider networks, compounding pharmacy routing, HIPAA compliance, and async clinical review are not capabilities most supplement operators have, and they do not need to build them. This operator launched a compliant peptide revenue channel in six weeks without hiring a single clinical employee. The first cohort validated pricing and structure at near-zero acquisition cost. Monthly recurring revenue exceeded any supplement launch in the brand's history within 90 days.

FuseHealth provides the infrastructure. The operator provides the brand and the audience. That division of responsibility is what makes this model work, and what makes it repeatable for any fitness brand with an existing community and documented demand in the clinical category.The peptide program launched six weeks after onboarding began. Monthly recurring revenue exceeded the best supplement product launch in the brand's history within 90 days. The brand did not hire any clinical staff. Prescription review, pharmacy fulfillment, and refill management ran through FuseHealth. The operator managed the community and acquisition strategy.

Refrences

American Med Spa Association Industry Report (2025) · FDA Compounding Pharmacy Guidance (2024–2025) · McKinsey & Company Consumer Health Survey (2024) · Wheel Virtual Care Report (2024)

Daniel Meursing

CEO

Daniel is a two-time founder who has scaled service businesses across major U.S. markets. A Y Combinator competition winner, he focuses on removing operational and regulatory barriers so operators can build and scale modern healthcare businesses. :

Background

Startup Operations & Service Systems

Experience

2x Founder, Multi-Market U.S. Scaling

Qualifications

Healthtech Infrastructure & Patient Access

Key Achievement

Scaled Premier Staff & Eventstaff across major U.S. markets